2025
A CD26+ tendon stem progenitor cell population contributes to tendon repair and heterotopic ossification
Chen S, Lin Y, Yang H, Li Z, Li S, Chen D, Hao W, Zhang S, Chao H, Zhang J, Wang J, Li Z, Li X, Zhan Z, Liu H. A CD26+ tendon stem progenitor cell population contributes to tendon repair and heterotopic ossification. Nature Communications 2025, 16: 749. PMID: 39820504, PMCID: PMC11739514, DOI: 10.1038/s41467-025-56112-5.Peer-Reviewed Original ResearchConceptsStem/progenitor cellsHeterotopic bone formationTendon stem/progenitor cellsHeterotopic ossificationTendon healingCell populationsStem-progenitor cell populationBone formationProgenitor cell populationsStem cell populationMultipotent differentiation potentialSubstantial painCD26Self-renewalDifferentiation potentialTenascin-CTendon repairHealingOssificationCellsTendonPainSuppressed chondrogenesis
2023
Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
Mashayekhi M, Nian H, Mayfield D, Devin J, Gamboa J, Yu C, Silver H, Niswender K, Luther J, Brown N. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes. Diabetes 2023, 73: 38-50. PMID: 37874653, PMCID: PMC10784656, DOI: 10.2337/db23-0356.Peer-Reviewed Original ResearchConceptsEndogenous GLP-1Glucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsImproved insulin sensitivityInsulin sensitivityGLP-1GLP-1RGlucagon levelsGlucose levelsMatsuda indexWeight lossHypocaloric dietPostprandial glucoseInhibitor sitagliptinReceptor agonistMetabolic effectsDiet-induced weight lossDipeptidyl peptidase-4 inhibitor sitagliptinGLP-1R agonist liraglutideWeight loss-independent effectsDPP-4 inhibitor sitagliptinDipeptidyl peptidase-4 inhibitionPeptidase-4 inhibitionMixed meal testGLP-1R antagonistThe KDM6A-KMT2D-p300 axis regulates susceptibility to diverse coronaviruses by mediating viral receptor expression
Wei J, Alfajaro M, Cai W, Graziano V, Strine M, Filler R, Biering S, Sarnik S, Patel S, Menasche B, Compton S, Konermann S, Hsu P, Orchard R, Yan Q, Wilen C. The KDM6A-KMT2D-p300 axis regulates susceptibility to diverse coronaviruses by mediating viral receptor expression. PLOS Pathogens 2023, 19: e1011351. PMID: 37410700, PMCID: PMC10325096, DOI: 10.1371/journal.ppat.1011351.Peer-Reviewed Original ResearchConceptsMouse hepatitis virusReceptor expressionTherapeutic targetMERS-CoVMajor SARS-CoV-2 variantsPrimary human airwaySARS-CoV-2 variantsNovel therapeutic targetViral receptor expressionSARS-CoV-2Histone methyltransferase KMT2DIntestinal epithelial cellsCoronavirus SusceptibilityDiverse coronavirusesHistone demethylase KDM6ADPP4 expressionCoronavirus receptorsHost determinantsHepatitis virusHuman airwaysSARS-CoVSmall molecule inhibitionViral entryPotential drug targetsViral receptorsDYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner
Strine M, Cai W, Wei J, Alfajaro M, Filler R, Biering S, Sarnik S, Chow R, Patil A, Cervantes K, Collings C, DeWeirdt P, Hanna R, Schofield K, Hulme C, Konermann S, Doench J, Hsu P, Kadoch C, Yan Q, Wilen C. DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner. PLOS Biology 2023, 21: e3002097. PMID: 37310920, PMCID: PMC10263356, DOI: 10.1371/journal.pbio.3002097.Peer-Reviewed Original ResearchConceptsGenome-wide CRISPR/Cas9 screenCRISPR/Cas9 screenPathogenic human coronavirusesKinase-independent mannerRegulated kinase 1AProviral host factorNovel drug targetsMultiple cell typesDNA accessibilityHost factorsKinase functionHuman coronavirusesHost genesDistal enhancerNovel regulatorCas9 screenKinase 1AGene expressionNeuronal developmentDYRK1ADrug targetsDiverse coronavirusesProviral activityCell typesSevere acute respiratory syndrome coronavirus 2
2022
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment
Wilson JR, Garner EM, Mashayekhi M, Hubers SA, Bustamante C, Kerman SJ, Nian H, Shibao CA, Brown NJ. DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment. Hypertension 2022, 79: 827-835. PMID: 35045722, PMCID: PMC8917054, DOI: 10.1161/hypertensionaha.121.18348.Peer-Reviewed Original ResearchMeSH KeywordsAdultAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensinsAprepitantBlood PressureCardiovascular AgentsCatecholaminesCross-Over StudiesDiabetes Mellitus, Type 2Dipeptidyl Peptidase 4HumansNorepinephrineRamiprilRenin-Angiotensin SystemSitagliptin PhosphateValsartanConceptsDPP4 inhibitionBlood pressureACE inhibitionDouble-blind crossover studyAcute ACE inhibitionBlood pressure armNK1 receptor blockerACE inhibitor treatmentOral diabetes medicationsCalcium channel blockersType 2 diabetesEffects of DPP4Aldosterone systemCardiovascular complicationsDiabetes medicationsReceptor blockersCardiovascular effectsCrossover therapyHeart failureHypotensive effectCrossover studyChannel blockersDPP4 inhibitorsHeart rateInhibitor treatment
2021
Skin Fibrosis and Recovery Is Dependent on Wnt Activation via DPP4
Jussila AR, Zhang B, Caves E, Kirti S, Steele M, Hamburg-Shields E, Lydon J, Ying Y, Lafyatis R, Rajagopalan S, Horsley V, Atit RP. Skin Fibrosis and Recovery Is Dependent on Wnt Activation via DPP4. Journal Of Investigative Dermatology 2021, 142: 1597-1606.e9. PMID: 34808238, PMCID: PMC9120259, DOI: 10.1016/j.jid.2021.10.025.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsbeta CateninDipeptidyl Peptidase 4FibroblastsFibrosisMiceSkinSkin DiseasesWnt Signaling PathwayConceptsWnt/β-catenin-responsive geneWnt activationExtracellular matrix homeostasisGenetic evidenceHuman fibrotic diseasesLipid-filled cellsFunctional mediatorsExtracellular matrixDermal adipocytesMatrix homeostasisGenetic modelsNew targetsWntKey targetMechanisms of fibrosisFibrotic diseasesTherapeutic avenuesDermal remodelingExtracellular matrix expansionExcessive accumulationRemodelingFibrosis severitySkin fibrosisFibrotic remodelingDPP4 inhibitorsImpact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin
Saffo S, Kaplan DE, Mahmud N, Serper M, John BV, Ross JS, Taddei T. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. Diabetes Obesity And Metabolism 2021, 23: 2402-2408. PMID: 34227216, PMCID: PMC8429193, DOI: 10.1111/dom.14488.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsDiabetes mellitusLiver diseaseNon-alcoholic fatty liver diseaseCotransporter 2 inhibitorsChronic liver diseaseFatty liver diseaseVeterans Affairs hospitalIncidence of ascitesAdditional pharmacotherapyTreat analysisElectronic health dataSGLT2 inhibitorsSGLT2i usersSurrogate biomarkerDPP4 inhibitorsMetabolic effectsPatientsCirrhosisPropensity scoreAscitesConfirmatory studiesMetformin
2020
Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition
Akoumianakis I, Badi I, Douglas G, Chuaiphichai S, Herdman L, Akawi N, Margaritis M, Antonopoulos AS, Oikonomou EK, Psarros C, Galiatsatos N, Tousoulis D, Kardos A, Sayeed R, Krasopoulos G, Petrou M, Schwahn U, Wohlfart P, Tennagels N, Channon KM, Antoniades C. Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition. Science Translational Medicine 2020, 12 PMID: 32350133, PMCID: PMC7212010, DOI: 10.1126/scitranslmed.aav8824.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAtherosclerosisCoronary Artery BypassDipeptidyl Peptidase 4HumansInsulinMiceOxidation-ReductionConceptsDipeptidyl peptidase-4 inhibitorsCoronary artery bypass surgeryAggressive insulin treatmentInsulin treatmentCoronary atherosclerosisEndothelial functionAbnormal responseHigh-fat diet-fed ApoEOral dipeptidyl peptidase-4 inhibitorLong-term combination therapyHuman internal mammary arteryDipeptidyl peptidase-4 inhibitionHigher cardiac mortalityPeptidase-4 inhibitionVascular insulin responsesVascular redox stateArtery bypass surgeryInternal mammary arteryInsulin resistance statusNitric oxide bioavailabilityPeptidase-4 inhibitorsPlasma DPP4 activityVascular oxidative stressRecent clinical trialsInsulin-sensitizing effectsInhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs
Srivastava SP, Goodwin JE, Kanasaki K, Koya D. Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs. Genes 2020, 11: 211. PMID: 32085655, PMCID: PMC7074526, DOI: 10.3390/genes11020211.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAnimalsCell LineDiabetes Mellitus, ExperimentalDiabetic NephropathiesDipeptidyl Peptidase 4Disease Models, AnimalDrug SynergismGene Expression RegulationHumansMiceMicroRNAsOligopeptidesSignal TransductionTransforming Growth Factor betaConceptsAngiotensin II receptor blockersRenal fibrosisDPP-4End-stage renal diseaseSubstrates of ACEDiabetic kidney diseaseEffect of ACEIII receptor blockersDPP-4 levelsTGFβ signalingAngiotensin converting enzymeChronic nephropathyReceptor blockersRenal diseaseKidney diseaseACEIEnzyme inhibitorsConventional drugsDownregulated expressionEndothelial cellsFibrosisInhibitory effectDrug 1MiR-29AcSDKP
2019
Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome
Devin JK, Nian H, Celedonio JE, Wright P, Brown NJ. Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome. The Journal Of Clinical Endocrinology & Metabolism 2019, 105: dgz028. PMID: 31529097, PMCID: PMC7947776, DOI: 10.1210/clinem/dgz028.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBiomarkersBlood GlucoseCross-Over StudiesDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsDouble-Blind MethodFemaleFollow-Up StudiesGlucose Tolerance TestHuman Growth HormoneHumansIntra-Abdominal FatMiddle AgedPolycystic Ovary SyndromePrognosisSitagliptin PhosphateYoung AdultConceptsOral glucose tolerance testPolycystic ovarian syndromeVisceral adiposityVascular functionGrowth hormoneOvarian syndromeGH secretionGlucagon-like peptide-1Increased visceral adiposityMaximal glucose responseOvernight GH secretionOvernight growth hormoneEarly insulin secretionGlucose tolerance testVenous samplingCrossover studyVisceral fatCrossover treatmentTolerance testBlood glucoseDPP4 inhibitionInsulin secretionPeak glucoseGlucose levelsPeptide-1In vivo, ex vivo and in vitro evidence for atropine-mediated attenuation of glucagon-like peptide-1 secretion: findings from a systematic review
Rathish D, Agampodi S, Jayasumana C. In vivo, ex vivo and in vitro evidence for atropine-mediated attenuation of glucagon-like peptide-1 secretion: findings from a systematic review. Environmental Science And Pollution Research 2019, 26: 29597-29605. PMID: 31446595, DOI: 10.1007/s11356-019-06227-2.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1GLP-1 secretionGlucagon-like peptide-1 secretionDipeptidyl peptidase-4 (DPP-4) enzymeRole of atropineVivo studiesPeptide-1 secretionRisk of biasPostprandial glucose homeostasisEx vivo studyPostprandial secretionCholinergic pathwaysAnticholinergic agentsCochrane LibraryHealthy menMuscarinic receptorsGlucose homeostasisPeptide-1Reference listsCompetitive antagonistHuman studiesAnimal studiesPRISMA statementSystematic reviewAtropine
2018
Dipeptidyl Peptidase‐4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women
Wilson JR, Brown NJ, Nian H, Yu C, Bidlingmaier M, Devin JK. Dipeptidyl Peptidase‐4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women. Journal Of The American Heart Association 2018, 7: e008000. PMID: 29478970, PMCID: PMC5866333, DOI: 10.1161/jaha.117.008000.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultCross-Over StudiesDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsDouble-Blind MethodFemaleFibrinolysisHuman Growth HormoneHumansInsulin-Like Growth Factor IMaleSecretory PathwaySex FactorsSitagliptin PhosphateTime FactorsTissue Plasminogen ActivatorUp-RegulationVasodilationYoung AdultConceptsFree insulin-like growth factor-1Insulin-like growth factor-1Growth factor-1GH secretionGrowth hormoneGHR blockadeVascular resistanceFactor 1Nitric oxideTissue plasminogen activator activityPeptidase-4 inhibitionImpaired endothelial functionGrowth hormone secretionReceptor-dependent effectsDipeptidyl peptidase-4Study drugEndothelial functionPlasminogen activator activityCrossover studyHormone secretionPeptidase-4VasodilationHealthy adultsGH receptorInhibition potentiates
2017
Adipocyte Accumulation in the Bone Marrow during Obesity and Aging Impairs Stem Cell-Based Hematopoietic and Bone Regeneration
Ambrosi T, Scialdone A, Graja A, Gohlke S, Jank A, Bocian C, Woelk L, Fan H, Logan D, Schürmann A, Saraiva L, Schulz T. Adipocyte Accumulation in the Bone Marrow during Obesity and Aging Impairs Stem Cell-Based Hematopoietic and Bone Regeneration. Cell Stem Cell 2017, 20: 771-784.e6. PMID: 28330582, PMCID: PMC5459794, DOI: 10.1016/j.stem.2017.02.009.Peer-Reviewed Original ResearchMeSH KeywordsAdipocytesAgingAnimalsBone MarrowBone RegenerationDipeptidyl Peptidase 4HematopoiesisMiceMice, TransgenicObesityConceptsStem cell-basedHematopoietic regenerationAdipocyte accumulationStem cell-like characteristicsCell-like characteristicsBone resident cellsDipeptidyl peptidase-4Bone marrow cavityCompetitive repopulationLethal irradiationHematopoietic nicheBone marrowCell-basedPeptidase-4Osteogenic lineageAged animalsBone healingDiabetes therapyAdipocyte lineageBoneMarrow cavityAge-dependentMolecular identityObesityAdipogenic lineages
2014
A three‐gene panel that distinguishes benign from malignant thyroid nodules
Zheng B, Liu J, Gu J, Lu Y, Zhang W, Li M, Lu H. A three‐gene panel that distinguishes benign from malignant thyroid nodules. International Journal Of Cancer 2014, 136: 1646-1654. PMID: 25175491, DOI: 10.1002/ijc.29172.Peer-Reviewed Original ResearchAdultAgedBiomarkers, TumorCarbonic AnhydrasesDatasets as TopicDiagnosis, DifferentialDipeptidyl Peptidase 4FemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeuroendocrine Secretory Protein 7B2PrognosisReproducibility of ResultsThyroid NeoplasmsThyroid NoduleYoung AdultSubstance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition
Devin JK, Pretorius M, Nian H, Yu C, Billings FT, Brown NJ. Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition. Hypertension 2014, 63: 951-957. PMID: 24516103, PMCID: PMC3984385, DOI: 10.1161/hypertensionaha.113.02767.Peer-Reviewed Original ResearchMeSH KeywordsAdultAngiotensin-Converting Enzyme InhibitorsBlood PressureBradykininCross-Over StudiesDipeptidyl Peptidase 4Double-Blind MethodEnalaprilatEnzyme InhibitorsFemaleHeart RateHumansMaleMiddle AgedNeurotransmitter AgentsNorepinephrinePeptidyl-Dipeptidase APyrazinesSitagliptin PhosphateSubstance PSympathetic Nervous SystemTriazolesVascular ResistanceConceptsDipeptidyl peptidase-4 inhibitionPeptidase-4 inhibitionTissue plasminogen activator releaseSubstance PDipeptidyl peptidase-4Plasminogen activator releaseSympathetic activityPeptidase-4Activator releasePlacebo-controlled crossover studyDipeptidyl peptidase-4 inhibitorsType 2 diabetes mellitusIntra-arterial enalaprilatForearm vascular resistanceForearm blood flowMean arterial pressurePeptidase-4 inhibitorsAngiotensin converting enzymeSubstrates of angiotensinVascular resistanceVasodilator responseArterial pressureBrachial arteryDiabetes mellitusCrossover study
2010
Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans
Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans. Hypertension 2010, 56: 728-733. PMID: 20679179, PMCID: PMC3305047, DOI: 10.1161/hypertensionaha.110.156554.Peer-Reviewed Original ResearchMeSH KeywordsAdultAldosteroneAngiotensin-Converting Enzyme InhibitorsBlood GlucoseBlood PressureDiabetes Mellitus, Type 2Dipeptidyl Peptidase 4Dose-Response Relationship, DrugDouble-Blind MethodDrug InteractionsDrug Therapy, CombinationEnalaprilFemaleHeart RateHemodynamicsHumansInsulinMaleMetabolic SyndromeMiddle AgedPeptidyl-Dipeptidase AProspective StudiesPyrazinesRenal CirculationSitagliptin PhosphateSodiumTriazolesConceptsDipeptidyl peptidase IV inhibitionACE inhibitionHypotensive responseHemodynamic effectsBlood pressureHeart rateSerum dipeptidyl peptidase IV activityAngiotensin-Converting Enzyme InhibitionAcute ACE inhibitionVasoconstrictor neuropeptide YBlood pressure responseRenal blood flowSympathetic nervous systemType 2 diabeticsCross-over fashionDipeptidyl peptidase IV inhibitorsDose-dependent effectDipeptidyl peptidase IV activityDose-dependent mannerPeptidase IV inhibitorsPeptidase IV activityMetabolic syndromeNorepinephrine concentrationsIncretin hormonesNeuropeptide YAssociation of angiotensin‐converting enzyme inhibitor‐associated angioedema with transplant and immunosuppressant use
Byrd JB, Woodard‐Grice A, Stone E, Lucisano A, Schaefer H, Yu C, Eyler AE, Salloum NE, Brown NJ. Association of angiotensin‐converting enzyme inhibitor‐associated angioedema with transplant and immunosuppressant use. Allergy 2010, 65: 1381-1387. PMID: 20557296, PMCID: PMC3305268, DOI: 10.1111/j.1398-9995.2010.02398.x.Peer-Reviewed Original ResearchConceptsACE inhibitor-associated angioedemaEnzyme (ACE) inhibitor-associated angioedemaTransplant patientsImmunosuppressant useDipeptidyl peptidase IV activityPeptidase IV activityTransplant statusDPPIV activityCardiac transplant patientsRenal transplant patientsChronic renal failureAssociation of angiotensinEffects of immunosuppressantsIncidence of angioedemaActivity of DPPIVCardiac transplantImmunosuppressant therapyRenal failureConsecutive patientsACE inhibitorsImmunosuppressant agentsAngioedema casesUnivariate analysisAngioedemaSeasonal allergies
2009
Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema
Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema. Hypertension 2009, 54: 516-523. PMID: 19581505, PMCID: PMC2758288, DOI: 10.1161/hypertensionaha.109.134197.Peer-Reviewed Original ResearchConceptsACE inhibitorsRisk of angioedemaVildagliptin useDPP-IV inhibitorsComparator-treated patientsEnzyme (ACE) inhibitor-associated angioedemaStudy drug exposureAngiotensin receptor blockersPhase III studyPossible drug-drug interactionsIncidence of angioedemaCase report formsDipeptidyl peptidase IV inhibitorsDrug-drug interactionsDPP-IV inhibitor vildagliptinPathogenesis of angiotensinPeptidase IV inhibitorsAngioedema riskClinical angioedemaReceptor blockersIII studyAbsolute riskAdjudication committeeDPP-IV inhibitionDrug exposure
2007
Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, Adam A, Brown NJ. Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema. Hypertension 2007, 51: 141-147. PMID: 18025295, PMCID: PMC2749928, DOI: 10.1161/hypertensionaha.107.096552.Peer-Reviewed Original ResearchConceptsEnzyme (ACE) inhibitor-associated angioedemaDipeptidyl peptidase IV activityHistory of angiotensinPeptidase IV activityControl subjectsSubstance PDipeptidyl peptidase IVEnzyme inhibitorsLife-threatening adverse effectsAngiotensin converting enzyme (ACE) inhibitorsEnzyme inhibitionAbsence of angiotensinPrevalence of smokingSera of patientsCase-control studyPeptidase IVSubstrates of angiotensinTissue edemaAssociated angioedemaAminopeptidase P activityVascular permeabilityAngioedemaAngiotensinAminopeptidase N activityAmino-terminal degradationDipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor–induced peritracheal edema
Byrd JB, Shreevatsa A, Putlur P, Foretia D, McAlexander L, Sinha T, Does MD, Brown NJ. Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor–induced peritracheal edema. Journal Of Allergy And Clinical Immunology 2007, 120: 403-408. PMID: 17531305, DOI: 10.1016/j.jaci.2007.04.012.Peer-Reviewed Original ResearchConceptsACE inhibitor-associated angioedemaDPPIV-deficient ratsMagnetic resonance imagingEdema formationSubstance PSerum dipeptidyl peptidase IV activityResonance imagingCaptopril-treated ratsSaline-treated ratsReceptor-dependent mechanismDipeptidyl peptidase IV activityPeptidase IV activityACE inhibitionSerial T2F344 ratsAnimal modelsEdemaAngioedemaDPPIV activityRatsDipeptidyl peptidase activityImpaired degradationSpantideDeficiencyMagnetic resonance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply